A: Yes! We offer in vitro and in vivo studies to evaluate efficacy, PK/PD, and toxicity. Biomarker analysis and histopathology provide mechanistic insights for regulatory submissions.

Introduction to Matrix Metalloproteinases (MMP)

MMPs are a family of calcium- and zinc-dependent endopeptidases critical for extracellular matrix (ECM) remodeling and tissue homeostasis. These Glycosyl Functional Enzymes, synthesized as inactive zymogens, are activated via proteolytic cleavage or allosteric mechanisms, enabling them to degrade collagens, elastins, and other ECM components. Beyond ECM turnover, MMPs regulate cell migration, angiogenesis, and immune responses by processing cytokines and growth factors. Dysregulation of these Glycosyl-Degrading Enzymes contributes to pathological processes, including cancer metastasis, arthritis, and cardiovascular diseases. Their activity is tightly controlled by tissue inhibitors of metalloproteinases (TIMPs), and targeting MMPs remains a promising therapeutic strategy for inflammatory and neoplastic disorders.

Fig. 1. TNF-α induces MMP-9 secretion in gastric carcinoma & peritoneal mesothelial cells. (OA Literature) Fig.1 TNF-α stimulates gastric carcinoma cells and peritoneal mesothelial cells to secrete MMP-9.¹

Service Overview

Are you currently facing high off-target toxicity in protease inhibitors, low specificity in substrate profiling, or inconsistent enzyme activity in complex biological matrices? Our MMP development service helps you obtain high-specificity peptide inhibitors and activity-validated recombinant enzymes through our proprietary allosteric site mapping and high-throughput zymogen activation platforms. Creative Biolabs accelerates your R&D by delivering biologically relevant data that bridges the gap between the bench and the clinic. More importantly, we specialize in the design and validation of MMP-targeted therapeutics, focusing on distinguishing between highly homologous family members like MMP-2 and MMP-9.

Explore Our Range of Support Services

MMP Development Workflow

Target Identification & Functional Validation
The development process begins with identifying MMP family members of therapeutic interest based on their role in disease pathology. Functional validation is performed using gene knockout/knockdown models, recombinant MMP overexpression systems, or pharmacological inhibitors to confirm the target's biological relevance and disease-modifying potential.

Recombinant Zymogen Production & Optimization
Pro-MMPs are expressed in mammalian or insect cell systems to ensure proper folding, disulfide bond formation, and zinc ion coordination. Expression vectors are engineered with affinity tags for purification. Process optimization includes scaling up fermentation, adjusting culture conditions, and implementing fed-batch strategies to maximize yield. Downstream purification involves immobilized metal affinity chromatography, ion exchange, and size-exclusion chromatography to obtain a highly pure, active zymogen.

Controlled Zymogen Activation & Enzymatic Characterization
The pro-domain is removed using specific proteases or chemical agents to generate active MMPs. Activation kinetics are monitored via SDS-PAGE or Western blotting. Enzymatic activity is quantified using FRET-based substrates, zymography, or collagen degradation assays. Detailed kinetic parameters are determined under varying conditions to establish baseline catalytic efficiency.

Substrate Specificity Profiling & Inhibitor Screening
High-throughput screening (HTS) is conducted against diverse substrate libraries to define MMP substrate preferences. Selectivity is assessed by testing cross-reactivity with related proteases. Differential scanning fluorimetry (DSF) or surface plasmon resonance (SPR) may be used to evaluate inhibitor binding affinity and selectivity. Lead compounds are prioritized based on potency, selectivity, and cell permeability.

Structural Biology & Rational Design
X-ray crystallography is employed to resolve MMP structures in complex with substrates/inhibitors. Computational modeling identifies allosteric sites or non-conserved regions for targeted inhibitor design. Structure-activity relationship (SAR) studies guide chemical modifications to improve potency, selectivity, and pharmacokinetic properties.

Stability, Modification & Formulation Development
Post-translational modifications are analyzed via mass spectrometry to understand their impact on enzyme stability, half-life, and tissue localization. Thermal stability assays assess conformational robustness. Formulation optimization focuses on solubility, stability, and delivery route to ensure bioavailability and minimize degradation.

Fig. 2. MMP development workflow. (Creative Biolabs AI) Fig.2 Schematic representation of MMP development.

Why Choose Us?

Expertise in MMP Biology & Target Validation
Our team combines deep knowledge of MMP structural biology with advanced functional assays to validate targets in disease models. We ensure your MMP-focused project is grounded in a robust scientific rationale, reducing development risks.

End-to-End Recombinant MMP Production
From zymogen expression in optimized mammalian/insect cell systems to high-purity purification, we deliver active MMPs tailored to your needs. Our scalable processes guarantee consistent yields for preclinical and clinical applications.

High-Throughput Screening & Selectivity Profiling
We leverage cutting-edge HTS platforms and protease panels to identify MMP-specific inhibitors with minimal off-target effects. Our comprehensive specificity mapping ensures your lead compounds are both potent and precise.

Structure-Guided Drug Design & Optimization
Using X-ray crystallography and computational modeling, we refine inhibitors to target non-conserved MMP domains. Our iterative SAR approach accelerates the development of high-affinity, selective therapeutics.

Preclinical & Toxicology Support
We offer integrated in vitro/in vivo studies to evaluate efficacy, pharmacokinetics, and safety. Our biomarker-driven assays and histopathology expertise provide critical data for regulatory submissions and clinical advancement.

Proven Track Record in MMP Therapeutics
With a history of successful MMP inhibitor projects, we understand the challenges of targeting this family. Our collaborative approach ensures transparency, flexibility, and alignment with your R&D goals.

Customer Reviews

Workflow Optimization
"Integrating the MMP development service into our research endeavors has markedly streamlined and optimized our workflow for MT-MMP studies, enhancing both efficiency and accuracy in our experimental processes."- 1 year ago, Dr. K***s.

Screening Expedition
"Leveraging the MMP development service in our research has greatly expedited and simplified our high-throughput screening process for TIMP-mimetics, enabling us to screen a larger number of compounds with greater speed and precision."- 8 months ago, Dr. R***t K.

Discover the Benefits of Our Help

FAQs

Q: What types of MMP-related services do you offer?

A: We provide end-to-end MMP development solutions, including recombinant MMP production, substrate/inhibitor screening, structural biology, lead optimization, and preclinical validation. Our services cover both therapeutic and research applications.

Q: How do you ensure the quality of recombinant MMPs?

A: Our mammalian/insect cell expression systems are optimized for proper folding. We use affinity purification, SEC, and activity assays to deliver highly pure, functional MMPs with batch-to-batch consistency.

Q: Can you help identify selective MMP inhibitors?

A: Absolutely! We screen compounds against a protease panel using HTS and DSF to map selectivity. Structure-guided design and SAR studies further refine inhibitors to target non-conserved domains, minimizing off-target effects.

Q: What structural biology techniques do you use for MMP projects?

A: We employ X-ray crystallography to resolve MMP structures in complex with substrates/inhibitors. Computational modeling identifies allosteric sites for rational drug design, accelerating lead optimization.

Q: Do you support preclinical MMP inhibitor testing?

A: Yes! We offer in vitro and in vivo studies to evaluate efficacy, PK/PD, and toxicity. Biomarker analysis and histopathology provide mechanistic insights for regulatory submissions.

Extended Services

Therapeutic Protein Glycoengineering

Our glycoengineering platform enables precise modification of therapeutic proteins to optimize their stability, pharmacokinetics, and immunogenicity.

Therapeutic Antibody Glycoengineering

We specialize in customizing antibody glycosylation to fine-tune antibody-dependent cellular cytotoxicity (ADCC), complement activation, and half-life.

Creative Biolabs provides an end-to-end ecosystem for MMP research, combining expert protein engineering with high-resolution analytical validation. Our goal is to empower your drug discovery and regenerative medicine projects with tools that define the future of proteolysis. For detailed project discussions and technical support, our team of specialists is ready to assist you. Contact us today!

Reference

Agren, Magnus S., and Ulrich auf dem Keller. "Matrix metalloproteinases: how much can they do?" International Journal of Molecular Sciences 21.8 (2020): 2678. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms21082678

For Research Use Only.

Related Services

Online Inquiry